Who Owns Razadyne?
Razadyne is a brand of galantamine owned by Johnson & Johnson through its Janssen Pharmaceuticals division. Originally launched as Reminyl and renamed Razadyne in the US in 2005, it is a cholinesterase inhibitor approved by the FDA in 2001 for mild to moderate Alzheimer's disease. Patents have long expired and galantamine is widely generic, leaving Razadyne as a legacy brand in J&J's neuroscience portfolio.
Parent Company
Founded
2001
Status
Publicly Traded
Headquarters
Razadyne Timeline
GlobalOfficial Website
Who Owns Razadyne?
- Parent Company: Johnson & Johnson
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: NYSE: JNJ
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Razadyne | Johnson & Johnson | Wholly owned |
Where to Buy
Disclosure: We may earn commission from purchases
Razadyne on AmazonAdvertisement
History of Razadyne
- Founded: 2001
- Founders: Janssen Pharmaceutica research
Galantamine's origins trace to the galantamine alkaloid isolated from snowdrop bulbs, studied for acetylcholinesterase inhibition in Eastern European research. Janssen Pharmaceutica, the Belgian J&J subsidiary, developed the compound as an Alzheimer's treatment through the 1990s, in partnership originally with Shire for some markets.
The FDA approved Reminyl in February 2001 for mild to moderate Alzheimer's disease, making it the third cholinesterase inhibitor on the US market after tacrine and donepezil. It launched internationally under the Reminyl name with co-promotion partners in various regions.
In 2005 the FDA required a name change in the US after dispensing errors confused Reminyl with the diabetes drug Amaryl (glimepiride). Janssen renamed the product Razadyne, introducing an extended-release formulation, Razadyne ER, the same period.
Patents expired and generic galantamine entered the US market in the late 2000s, rapidly eroding branded sales. Razadyne remains on the market as a legacy brand but is a minor line in J&J's neuroscience portfolio, which centers on newer products such as Spravato.
Advertisement
About Johnson & Johnson
Is Johnson & Johnson publicly traded?
Yes, Johnson & Johnson is publicly traded on the New York Stock Exchange under the ticker symbol JNJ. The company has been publicly traded since 1944 and is one of the most widely held healthcare stocks globally, included in major stock market indices including the Dow Jones Industrial Average.
What were Johnson & Johnson's FY2025 financial results?
J&J reported full-year 2025 sales of $94.2 billion, up 6.0% year-over-year, with net earnings of $26.8 billion and adjusted EPS of $10.79. Q4 2025 sales grew 9.1% to $24.6 billion. The company generated approximately $19.7 billion in free cash flow and increased its dividend for the 63rd consecutive year.
Who is Johnson & Johnson's CEO?
Joaquin Duato serves as Chairman and CEO of Johnson & Johnson. He became CEO in 2022 and described 2025 as a "catapult year" fueled by the strongest portfolio and pipeline in the company's history. Duato has focused J&J on six key therapeutic areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision.
What is Johnson & Johnson's 2026 outlook?
J&J issued 2026 guidance of $100.5 billion in estimated reported sales (6.7% growth at midpoint) and adjusted EPS of $11.53 (6.9% growth at midpoint). This guidance accounts for approximately $500 million in expected tariff impacts and a drug pricing agreement with the Trump administration.
Advertisement
What are Johnson & Johnson's main business segments?
J&J operates through two segments: Innovative Medicine (pharmaceuticals), which generated $60.4 billion in 2025 sales, and MedTech (medical devices), which contributed $33.8 billion. The company previously had a third Consumer Health segment, which was spun off as Kenvue in 2023.
What happened to Johnson & Johnson's consumer brands?
In 2023, J&J completed the spin-off of its consumer health business as Kenvue, which included Tylenol, Band-Aid, Johnson's Baby, Neutrogena, Aveeno, Listerine, and other consumer brands. Kenvue was fully separated in August 2023 via an IPO and exchange offer. These brands remain associated with J&J in public recognition.
What medical innovations did J&J achieve in 2025?
J&J secured FDA approval of CAPLYTA for major depressive disorder, approval of RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, and reported landmark data for TECVAYLI plus DARZALEX FASPRO for multiple myeloma. The company also acquired Halda Therapeutics and submitted the OTTAVA Robotic Surgical System for regulatory review.
What is the talc litigation status?
J&J faces thousands of lawsuits alleging its talc-based baby powder caused ovarian cancer and mesothelioma. In October 2025, a California jury awarded $966 million to a mesothelioma victim's family. In March 2025, a bankruptcy judge rejected J&J's proposed $8 billion settlement for ovarian cancer claims. The litigation remains ongoing.
Advertisement
- Founded: 1886
- Headquarters: New Brunswick, New Jersey, USA
- Company Type: Publicly Traded
- Stock: NYSE: JNJ
- Revenue: $94.2 billion (FY2025)
- Employees: Approximately 137,000
Where Is Razadyne Made / Based?
- Headquarters: New Brunswick, New Jersey, USA
Razadyne Categories & Tags
Razadyne Recalls & Controversies
The defining episode in Razadyne's history is the 2005 forced renaming from Reminyl after dispensing errors with the diabetes drug Amaryl caused medication mix-ups, including serious errors. The FDA required the change as a medication safety measure.
Galantamine was also studied and marketed for mild cognitive impairment until FDA warnings about increased mortality in MCI trials halted that indication pursuit. Standard cholinesterase inhibitor warnings appear in labeling. No major product recalls are on record.
Brands Owned by Johnson & Johnson
Healthcare PharmaceuticalsAcuvue
Owned by Johnson & Johnson
Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.
contact-lensesvision-carejohnson-and-johnson
Beauty Personal CareAveeno
Owned by Johnson & Johnson
American brand of skincare and hair care products specializing in natural ingredients and colloidal oatmeal formulations.
skincarenaturaloatmeal
Healthcare PharmaceuticalsBand-Aid
Owned by Johnson & Johnson
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
wound-careadhesive-bandagefirst-aid
Beauty Personal CareCarefree
Owned by Johnson & Johnson
American feminine hygiene brand producing panty liners and feminine care products, now owned by Essity, a Swedish global hygiene and health company.
feminine-hygienepanty-linerspersonal-care
Beauty Personal CareClean & Clear
Owned by Johnson & Johnson
American skincare brand producing facial cleansers, moisturizers, and acne treatments for teens and young women, owned by Kenvue Inc.
skincarefacial-cleanseracne-treatment
Healthcare PharmaceuticalsJohnson & Johnson MedTech
Owned by Johnson & Johnson
Johnson & Johnson's medical technology segment generating $33.8 billion in 2025 sales across surgery, orthopaedics, cardiovascular, and vision, including Ethicon and DePuy Synthes.
medical-devicesmedtechsurgical-instruments
Advertisement
Razadyne Ownership: Pros & Cons
Advantages
- +Backed by Johnson & Johnson's manufacturing and distribution scale
- +Established safety record over two decades
- +Remains an option for patients intolerant of other agents
Considerations
- -Generic competition eliminated branded revenue
- -No longer a strategic focus for J&J
- -Renaming history created lingering brand recognition issues
- -Cholinesterase inhibitor class is mature with limited growth
Frequently Asked Questions About Razadyne
Advertisement
Sources & Further Reading
Competitors to Razadyne
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Eisai | Japan | 1996 | Mass market | Global | All Genders | |
| Novartis | Switzerland | 1997 | Mass market | Global | All Genders | |
| Eli Lilly | USA | 2024 | Mass market | Global | All Genders | |
| Abbvie | USA | 2003 | Mass market | United states | All Genders | |
| Pfizer | USA | 2020 | Mass market | United states | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsAricept
Owned by Eisai
Brand name for donepezil, the most prescribed Alzheimer's disease cholinesterase inhibitor, developed by Eisai and formerly co-marketed with Pfizer.
neurologyalzheimersdementia
Healthcare PharmaceuticalsExelon
Owned by Novartis
Brand name for rivastigmine, a prescription cholinesterase inhibitor developed by Novartis for treating mild-to-severe Alzheimer's disease and Parkinson's disease dementia. Available as capsules, oral solution, and transdermal patch.
neurologyalzheimersdementia
Healthcare PharmaceuticalsKisunla
Owned by Eli Lilly and Company
Eli Lilly's donanemab, an anti-amyloid antibody for early Alzheimer's disease approved by the FDA in 2024, competing directly with Eisai and Biogen's Leqembi.
neurologyalzheimersdementia
Healthcare PharmaceuticalsNamenda
Owned by AbbVie Inc.
Brand name for memantine, an NMDA receptor antagonist for moderate-to-severe Alzheimer's disease, owned in the US by AbbVie through the Allergan acquisition.
neurologyalzheimersdementia
Healthcare PharmaceuticalsNurtec ODT
Owned by Pfizer Inc.
CGRP antagonist (rimegepant) for acute and preventive migraine treatment, acquired by Pfizer through the 2022 Biohaven acquisition for approximately $11.6 billion.
migrainecgrp-inhibitorneurology
Competitive Analysis
Market Positioning: Razadyne competes with 5 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Razadyne
Looking for brands with different ownership structures? These similar brands are not owned by Johnson & Johnson, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsAvaility
Owned by Availity
The largest real-time health information network in the US, owned by a consortium of major health insurers and Novo Holdings.
healthcare-technologyclearinghouseclaims-processing
Privately Owned
Availity is privately owned, unlike Razadyne which is under a publicly traded parent company.
Healthcare PharmaceuticalsBand-Aid
Owned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
wound-careadhesive-bandagefirst-aid
Privately Owned
Band-Aid is privately owned, unlike Razadyne which is under a publicly traded parent company.
Healthcare PharmaceuticalsBenadryl
Owned by Kenvue
American brand of antihistamine medication used to treat allergies, itching, and cold symptoms, manufactured and marketed by Johnson & Johnson.
antihistamineallergy-reliefcold-medicine
Privately Owned
Benadryl is privately owned, unlike Razadyne which is under a publicly traded parent company.
Healthcare PharmaceuticalsBoehringer Ingelheim
Owned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
pharmaceuticalsprescription-drugsanimal-health
Privately Owned
Boehringer Ingelheim is privately owned, unlike Razadyne which is under a publicly traded parent company.
Healthcare PharmaceuticalsBoots
Owned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
pharmacyhealth-beautyuk-retail
Privately Owned
Boots is privately owned, unlike Razadyne which is under a publicly traded parent company.
Healthcare PharmaceuticalsBrainlab
Owned by Brainlab SE
Munich surgical navigation and radiotherapy software brand installed in about 4,000 hospitals worldwide.
medical-technologysurgical-navigationradiosurgery
Privately Owned
Brainlab is privately owned, unlike Razadyne which is under a publicly traded parent company.
Johnson & Johnson Stock Information
Advertisement
Jobs at Johnson & Johnson
Latest News About Razadyne
Advertisement
Related Articles About Razadyne
View more articles
Health
The Pharmaceutical Giants Behind Common Medicines
Eli Lilly is now #1 pharma ($65.2B, Mounjaro + Zepbound). Novo Nordisk has 59.6% GLP-1 share. Merck's Keytruda is $31.7B. Pfizer faces a $20B patent cliff. Discover who makes your medicines. Explore our database.
Who Brands StaffNov 6, 2026
PharmaceuticalsEli LillyNovo Nordisk
Same Company
Your Entire Medicine Cabinet Might Be J&J
Tylenol, Band-Aid, Listerine, Neutrogena, Aveeno, Benadryl. Johnson & Johnson's consumer health portfolio is extensive. Here is a complete look at the brands now under Kenvue.
Who Brands StaffApr 4, 2026
Johnson And JohnsonKenvueConsumer Health
Industry Analysis
Who Owns the Sunscreen Market
Beiersdorf owns Nivea Sun and Coppertone. L'Oreal owns La Roche-Posay and Anthelios. Edgewell owns Banana Boat and Hawaiian Tropic. Here is who controls the global sunscreen market in 2026.
Who Brands StaffMar 23, 2026
SunscreenSun CareBeauty
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandmedical-devices
Abbott Medical Devices
Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.
Brand in Healthcare & Pharmaceuticals
cardiovasculardiabetes-care
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization